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Antisense basic fibroblast growth factor
gene transfer reduces early intimal
thickening in a rabbit femoral artery
balloon injury model
David G. Neschis, MD, Shawn D. Safford, MD, Abigail K. Hanna, MD,
Jonathan C. Fox, MD, PhD, and Michael A. Golden, MD, Philadelphia, Pa.
Purpose: The purpose of this study was to determine whether endogenous basic fibro-
blast growth factor (bFGF) production contributes to the intimal hyperplastic response
to injury in a model of rabbit femoral artery balloon injury. Inhibition of de novo pro-
duction of bFGF protein was targeted by intramural adenoviral gene transfer of anti-
sense bFGF (Ad.ASbFGF) RNA. The adenovirus was delivered locally intraluminally at
the time of arterial injury.
Methods: New Zealand White rabbits underwent balloon injury of the superficial femoral
artery, followed by intraluminal delivery of an adenoviral vector encoding a rat antisense
bFGF (ASbFGF) transcript at a concentration of 1 ´ 1010 plaque-forming units per mil-
liliter. Control animals were treated in a similar fashion, using either an adenovirus
encoding the lac Z reporter gene (Ad.lacZ) or phosphate-buffered saline solution (PBS;
vehicle) alone. Two weeks after balloon injury, rabbits were killed and perfusion fixed.
Femoral arteries were harvested for histomorphometric analysis. Intimal and medial wall
thickness was measured at eight points around the vessel perimeter, and mean inti-
mal/medial (I/M) thickness ratios were compared by analysis of variance and Student’s
t test. In addition, medial cell proliferation in Ad.ASbFGF and Ad.lacZ treated arteries
was evaluated 4 days and 2 weeks after balloon injury by 5-Bromo-2’-deoxyuridine
labeling.
Results: At 14 days (n = 25) after balloon injury, histomorphometric analysis revealed a
significant inhibition of intimal thickening in Ad.ASbFGF-treated arteries as compared
with Ad.lacZ-treated and PBS-treated controls (I/M thickness ratios ± SD, 0.43 ± 0.22
for Ad.ASbFGF vs 1.03 ± 0.28 for Ad.lacZ and 0.86 ± 0.19 for PBS; p < 0.0001 and p
= 0.004, respectively). There was no significant difference in the I/M thickness ratios of
Ad.lacZ-treated and PBS-treated vessels (p = 0.27). Although there was no significant
difference in the proliferation index of Ad.ASbFGF-treated and Ad.lacZ-treated vessels
4 days after injury, an increase in apoptosis was noted in the Ad.ASbFGF-treated vessels
4 days after balloon injury.
Conclusions: The use of ASbFGF RNA gene transfer, designed to inhibit de novo bFGF
synthesis after balloon injury, results in a significant inhibition of neointimal formation.
This suggests that continued bFGF synthesis contributes to the arterial response to
injury in rabbits. ASbFGF gene transfer may be an effective strategy in limiting the inti-
mal hyperplastic response after vascular reconstructive procedures. (J Vasc Surg
1998;27:126-34.)
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Despite numerous advances in the treatment of
the lesions of atherosclerosis by both bypass grafting
and angioplasty, restenosis continues to threaten
clinical results. Recent reports describe the resteno-
sis rate 6 months after coronary angioplasty to be as
high as 43% to 57%.1,2 A variety of strategies have
been developed to target the hyperplastic response
to injury in an effort to minimize the resulting
restenotic lesion. The process of intimal hyperplasia
is generally accepted to involve the adherence and
activation of platelets at the site of vascular injury
with the subsequent release of growth factors from
both platelets and injured smooth muscle cells
(SMCs), resulting in SMC migration to the neointi-
ma associated with cellular proliferation and extra-
cellular matrix deposition.
In recent years, the targeting of growth factors
involved in the injury response has been the subject
of intense investigation. Lindner and Reidy3 have
demonstrated that the systemic administration of a
neutralizing antibody against basic fibroblast growth
factor (bFGF) at the time of carotid balloon injury
in rats results in a significant reduction in the SMC
proliferation index 2 days after balloon injury with-
out a significant reduction in intimal thickening 8
days after injury. Their study further identifies bFGF
as an important mitogen that controls the growth of
vascular SMCs, but the study also demonstrates that
neutralization of bFGF released from cells at the
time of injury alone is insufficient in reducing inti-
mal thickening after balloon injury. Along with
other studies, their data provide strong evidence that
endogenous bFGF released by injured and dying
cells is a major factor in the intimal hyperplastic
response.4,5
The role of de novo bFGF production by cells in
the arterial wall after initial injury is less clear.
Although Lindner and Reidy3 did not demonstrate a
reduction in intimal thickening 8 days after injury in
rats that received neutralizing antibody against
bFGF at the time of carotid balloon injury, Nguyen
and colleagues6 were able to demonstrate suppres-
sion of the neointimal lesion 14 days after aortic
injury in rabbits that received anti-bFGF antibody
daily from 30 minutes before injury to 5 days after
injury. It had been previously thought because of the
absence of a classic secretory signal peptide that
bFGF is not a secreted cell product and is therefore
only released by cells that undergo injury or death.7
However, there is evidence that bFGF can exit viable
cells by a mechanism independent of the classic
endoplasmic reticulum–Golgi complex secretory
pathway.8-10
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We have previously shown, using an adenoviral
vector encoding a full-length antisense bFGF
(Ad.ASbFGF) sequence, that there is a dose-depen-
dent reduction in intimal thickening in rat carotid
arteries treated locally with Ad.ASbFGF at the time
of balloon injury.11 These results suggest that de
novo production of bFGF in surviving SMCs plays
an important role in the rat carotid arterial response
to injury.
We believed it was important to study the role of
de novo bFGF synthesis in the arterial response to
injury in a second animal model, particularly the
rabbit femoral artery model, for several reasons. The
rat carotid balloon injury model is well described
and has been a major tool in the study of the arteri-
al response to injury.12 A limitation of this model lies
in the observation of significant variation between
species in the response to a particular intervention.
It has been reported that profound effects on intimal
thickening in rats as a result of a drug or other inter-
vention have not always been reproduced in larger
animals.13,14 An ability to reproduce a biologic
effect in a second, larger, animal model may suggest
an increased likelihood of a similar effect in the clin-
ical setting. Because there are differences in the bio-
logic properties of different vessels, concern was
raised as to whether the response of the carotid
artery would predict the response of another vessel
such as the femoral artery, which currently is a more
common site for procedures involving balloon
injury. In addition, as it has been suggested that the
desired effect of adenoviral based gene therapy may
be limited, particularly in rabbit femoral arteries, by
the associated inflammatory response,15 studies of
potential gene therapeutics in similar models are
warranted. The current study was designed to eval-
uate the role of de novo bFGF production in the
arterial response to injury in a rabbit femoral balloon
injury model. In addition to studying the altered
response to injury in terms of intimal thickening, we
studied the effects of ASbFGF on cellular prolifera-
tion and the role of continued bFGF production on
cellular viability and apoptosis.
METHODS
Rabbit femoral artery injury model. All ani-
mal procedures were approved by the Animal Care
and Use Committee of the University of
Pennsylvania, and complied with the Guide for the
Care and Use of Laboratory Animals from the
Institute of Laboratory Animal Resources,
Commission on Life Sciences, National Research
Council (Washington: National Academy Press,
1996). Adult male New Zealand White rabbits
(Hazelton Research Products, Inc., Denver, Pa.)
weighing approximately 3 to 4 kg were used in all
experiments. The animals were housed in a virus-
free and Pasteurella-free facility. Anesthesia was
induced by intramuscular injection of ketamine (50
mg/kg; Phoenix Scientific Inc., St. Joseph, Mo.),
xylazine (5 mg/kg; Phoenix Scientific Inc.), and
acepromazine maleate (1 mg/kg; Fermenta Animal
Health Co., Kansas City, Mo.). Additional doses
equivalent to one half the initial dose of ketamine
and xylazine were given when required.
Both superficial femoral arteries were exposed
medially and isolated from the inguinal ligament
to the knee. Microvascular clamps were placed on
the superficial femoral artery proximally and on
the popliteal and genu suprema arteries distally.
The great saphenous artery was tied off distally
with braided polyester suture. All small side
branches were ligated, as well. An arteriotomy was
made in the great saphenous artery proximal to
the tie, and a 2F Fogarty arterial embolectomy
catheter (Baxter Healthcare Corp., Irvine, Calif.)
was passed up the superficial femoral artery. The
balloon was inflated and withdrawn three times to
create a controlled injury of the vessel wall. After
removal of the catheter, the isolated superficial
femoral artery was irrigated with sterile phos-
phate-buffered saline solution (PBS; Bio-
Whittaker, Walkersville, Md.) via a 24-gauge
Angiocath (Becton-Dickinson Vascular Access,
Sandy, Utah). After irrigation, approximately 200
ml of either Ad.ASbFGF at 1 ´ 1010 plaque-form-
ing units (pfu)/ml concentration, control virus
encoding the b-galactosidase gene (Ad.lacZ) at 1 ´
1010 pfu/ml concentration, or PBS vehicle alone
was delivered intraluminally via a 24-gauge
Angiocath at a pressure sufficient to gently but
firmly distend the superficial femoral artery for 20
minutes. After that time, the solution was removed
and the vessel was flushed briefly by controlled
removal of the proximal clamp, followed by liga-
tion of the great saphenous artery and restoration
of flow via the popliteal and genu suprema arter-
ies. Ties on the side branches were used as land-
marks for the recording of the location of injury
and vector delivery, which were of similar extent.
The wound was closed in two layers with
absorbable suture, and the animals were allowed
to recover under supervision. After recovery, ani-
mals were allowed standard chow and water ad
libitum. All suture materials were a generous gift
from the United States Surgical Corporation.
Adenoviral vectors. The Ad.ASbFGF recombi-
nant adenovirus was constructed by replacement of
the b-galactosidase cDNA with a 1.1 kb rat bFGF
cDNA (in the antisense orientation) in the
pAd.CMV lac Z shuttle vector, followed by homol-
ogous recombination with the E1, E3 deleted,
human adenovirus serotype 5 mutant dl7001 in
human embryonal kidney 293 cells, as previously
described.16 Rat and rabbit bFGF is approximately
90% homologous.17
The control virus for all experiments was a repli-
cation-deficient recombinant adenoviral vector
encoding the bacterial b-galactosidase reporter gene
(gift of Dr. James Wilson, University of
Pennsylvania).18 In addition, PBS vehicle alone was
used as a second control.
Tissue preparation. Fourteen days after balloon
injury the animals were deeply anesthetized as
described above, and 2.5 ml of 5.0% Evans blue
(Sigma, St. Louis) was administered intravenously
20 minutes before death. By staining deendothelial-
ized vessels a deep blue, the adequacy of the balloon
injury was confirmed in all animals studied. The
aorta and vena cava were then exposed via a midline
incision, and the aorta was cannulated. The animal
was then exsanguinated via an incision in the vena
cava followed by anterograde perfusion via the aorta
with lactated Ringer’s solution at 120 to 150 mm
Hg pressure until the effluent was clear. This was
immediately followed by perfusion fixation with 10%
neutral buffered formalin at the same pressure until
the hindlimbs were stiff. Segments of superficial
femoral arteries that were both deendothelialized
and in the regions exposed to treatment solution
were excised and immersion-fixed in 10% neutral
buffered formalin for at least 24 hours. Thereafter,
three segments were taken from each vessel and
were paraffin-embedded, sectioned, and stained
with hematoxylin and eosin. Cross-sections of each
segment were examined under light microscopy, and
quantitation of the intimal thickness, medial thick-
ness, and intima/media (I/M) thickness ratio at
eight circumferential points around each section was
obtained by computerized planimetry using Summa
Sketch II Plus from Summagraphics Corp.
(Seymour, Conn.) and BioQuant System IV soft-
ware from R+M Biometrics, Inc. (Nashville, Tenn.).
Mean values for each artery were calculated.
In vivo quantitation of proliferation; 5-
bromo-2-deoxyuridine (BrdU) labeling. To study
proliferation in vivo, rabbits received an intramuscu-
lar dose of BrdU (50 mg/kg; Boehringer
Mannheim Corp., Indianapolis) at 19 hours, 8
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hours, and 1 hour before death. BrdU, a thymidine
analog, is taken up by proliferating cells and can be
visualized by immunohistochemical techniques.
Arterial and small intestinal segments (positive con-
trol) were paraffin-embedded, sectioned, and incu-
bated with antibody to BrdU at 10 mg/ml concen-
tration. BrdU incorporation into cellular DNA was
detected as previously described19 using an avidin-
peroxide complex (Vector Laboratories, Burlin-
game, Calif.) and 3,3 diaminobenzidine substrate
(Sigma). Slides were counterstained with hema-
toxylin to enable counting of the total number of
cells in each compartment. The proliferative index
was calculated as the percent BrdU-positive cells in
the media of vessels 4 days after balloon injury and
in the intima and media of vessels harvested 2 weeks
after injury. Means from Ad.ASbFGF-treated and
Ad.lacZ-treated controls were compared.
Evaluation of gene transfer using the lac Z
reporter gene. In a subset of animals killed 4 days
after balloon injury, the superficial femoral arteries
were harvested before perfusion fixation. Segments
of artery from a site known to have been both bal-
loon-injured and exposed to treatment solution
were excised, briefly washed in PBS, and frozen in
OCT compound (Miles Inc., Elkhart, Ind.) in a 2-
methylbutane/dry ice bath. Samples were then
thawed, rinsed in PBS, and fixed in 0.5% glutaralde-
hyde for 15 minutes, then washed twice for 10 min-
utes each with 1 mmol/L MgCl2 in PBS at room
temperature. The samples were then incubated in 5-
Bromo-4-chloro-3-indolyl-b-D-galactopyranoside
(X-gal) chromagen solution containing X-gal (1
mg/ml; Boehringer Mannheim), 5 mmol/L
K3Fe(CN)6, 5 mmol/L K4Fe(CN)6, and 1 mmol/L
MgCl2 in PBS for 30 to 60 minutes at 37° C. The
X-gal chromagen stains the b-galactosidase product
of the lac Z gene blue and confirms gene transfer
and protein production. Gross sections were exam-
ined en face under a Leitz dissecting photomicro-
scope (Leica Inc., Malvern, Pa.), and similar seg-
ments were paraffin-embedded, cross-sectioned, and
counterstained with nuclear-fast red for photomicro-
scopic examination.
Evaluation of apoptosis. Identification of
apoptotic cells in the vascular wall was performed by
terminal deoxynucleotidyl transferase (TdT)-medi-
ated 2’-deoxy-uridine-5’-triphosphate nick end
labeling (TUNEL). This procedure involves the
incorporation of labeled nucleotides to DNA strand
breaks in situ, allowing visualization of DNA frag-
mentation characteristic of apoptosis by fluorescence
microscopy. Paraffin-embedded, formalin-fixed
cross-sections were heated to 60° C for 10 minutes,
deparaffinized, and gradually rehydrated using
decreasing concentrations of ethanol. Sections were
then incubated in 20 mg/ml proteinase K
(Boehringer Mannheim) for 30 minutes at 37° C.
Samples were then washed twice in PBS and incu-
bated in TUNEL reaction buffer containing fluores-
cein-isothiocyanate (FITC)-uTP and TdT according
to the manufacturer’s instructions (Boehringer
Mannheim). After a 60-minute incubation with the
TUNEL reaction mixture at 37° C in the dark, sec-
tions were rinsed three times in PBS and counter-
stained by brief exposure to 1 mg/ml concentration
propidium iodide (Sigma) and PBS rinsing. Samples
from Ad.ASbFGF-treated and Ad.lacZ-treated ves-
sels 4 days and 2 weeks after balloon injury were
immediately examined by indirect fluorescence
microscopy.
Data analysis. Results are reported as mean ±
SD. Mean values among Ad.ASbFGF, Ad.lacZ, and
PBS treatment groups were compared using analysis
of variance. Differences in mean values between
individual groups were compared using a two-tailed
Student’s unpaired t test and were confirmed by
pairwise comparison using the Student-Newman-
Keuls Method (SigmaStat software, Jandel
Scientific, San Rafael, Calif.). Differences were con-
sidered significant for p values less than 0.05. All
experiments were performed in a blinded fashion
such that the balloon injury was performed before
random selection of the treatment agent. Planimetry
was performed in blinded fashion, as well, and was
confirmed by a blinded observer.
RESULTS
Evaluation of lac Z transgene expression.
Multiple discontinuous segments were obtained
from superficial femoral arteries 4 days after balloon
injury and vector delivery. After processing with X-
gal chromagen as described above, vessels treated
with Ad.lacZ at a concentration of 1 ´ 1010 pfu/ml
demonstrated deep blue staining across the full
extent of each segment studied (Fig. 1, A), indicat-
ing successful gene transfer along the length of the
treated vessel. A sharp demarcation at the border of
treated and nontreated areas is noted, as well. To
determine the depth of gene delivery within the vas-
cular wall, X-gal–stained arterial segments were
cross-sectioned, counterstained, and viewed under a
light microscope. These sections revealed greater
than 90% gene transfer efficiency with delivery
through the full thickness of the vessel media and
occasional staining within the adventitia (Fig. 1, B).
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Control vessel segments not treated with Ad.lacZ
did not stain positively when treated with X-gal
chromagen.
Limitation of intimal thickening via
Ad.ASbFGF delivery. To determine the effects of
Ad.ASbFGF delivery on the arterial response to
injury, superficial femoral vessels (n = 25) were har-
vested from rabbits 14 days after balloon injury and
delivery of either Ad.ASbFGF at 1 ´ 1010 pfu/ml,
Ad.lacZ at 1 ´ 1010 pfu/ml, or PBS vehicle alone.
Three segments per vessel from areas that were both
injured and exposed to treatment solution were ana-
lyzed by light microscopy after fixation, cross-sec-
tioning, and staining. The thickness of the intimal
and medial layers were measured by computerized
planimetry at eight points around the circumference
of the cross section. Mean I/M thickness ratios were
obtained for each vessel, and the treatment groups
were compared (Fig. 2). Histomorphometric analy-
sis revealed a significant limitation of intimal thick-
ening in Ad.ASbFGF-treated arteries as compared
with Ad.lacZ-treated and PBS-treated control speci-
mens (I/M thickness ratios ± SD, 0.43 ± 0.22 vs
1.03 ± 0.28 for Ad.lacZ and 0.86 ± 0.19 for PBS; p
< 0.0001 and p = 0.004, respectively). There was no
significant difference in the I/M thickness ratios of
Ad.lacZ-treated and PBS-treated vessels (p = 0.27;
Fig. 3). Analysis of variance was used to compare
mean values among the three treatment groups (p <
0.0001).
Investigation of mechanisms involved in
Ad.ASbFGF-mediated reduction of intimal
thickening response to balloon injury. At 4 days
(n = 9) and 14 days (n = 8) after balloon injury, ves-
sels were harvested from animals that received
BrdU. Cross-sections of fixed and paraffin-embed-
ded vessels were stained for BrdU and examined by
light microscopy. BrdU-positive and BrdU-negative
cells were counted in the media of entire sections at
4 days and from four high-power fields (over 400
cells per section counted) in the intima and media of
sections harvested at 14 days after balloon injury and
vector delivery. Results from vessels treated with
Ad.ASbFGF at 1 ´ 1010 pfu/ml and Ad.lacZ at 1 ´
1010 pfu/ml were compared. The results demon-
strated a decline in the medial proliferation index
A
Fig. 1. A, En face views of luminal surface of multiple discontinuous segments of a single rab-
bit superficial femoral artery treated with Ad.lacZ at 1 ´ 1010 pfu/ml via 20 minute local intra-
luminal incubation and stained with X-gal chromagen 4 days after balloon injury and vector
delivery. These images demonstrate successful gene delivery and protein production along the
full length of the treated vessel. Note segment in upper left image that demonstrates demar-
cation between treated and nontreated zones. Original magnification, ´7.5. B, Cross-section-
al photomicrograph of a segment of rabbit superficial femoral artery treated with Ad.lacZ at 1
´ 1010 pfu/ml via 20 minute local intraluminal incubation and stained with X-gal chromagen
4 days after balloon injury and vector delivery. Segments were then embedded, sectioned, and
counterstained with nuclear-fast red. This image demonstrates greater than 90% gene transfer
efficiency with gene delivery through the thickness of the media. Original magnification, ´125.
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from 4 days after injury to 14 days after injury in
both the Ad.ASbFGF-treated group (from 23% at 4
days to 10% at 14 days) and in the Ad.lacZ-treated
group (from 36% at 4 days to 10% at 14 days). There
did not appear to be a statistically significant differ-
ence between the medial proliferation index at 4
days in the Ad.ASbFGF-treated group compared
with the Ad.lacZ-treated group (23% vs 36%; p =
0.15). At 14 days after injury there does not appear
to be a significant difference in the proliferation
index between the Ad.ASbFGF-treated group and
the Ad.lacZ-treated group in either the intima (21%
vs 13%; p = 0.35) or the media (10% in both
groups).
Sections from the same vessels studied by BrdU
incorporation were also evaluated by the TUNEL
reaction to investigate the presence of apoptotic cells
in the vessel walls after balloon injury and gene
delivery. Increased numbers of apoptotic cells were
found in the media of Ad.ASbFGF-treated vessels 4
days after injury as compared with vessels treated
with Ad.lacZ (Fig. 4). By 2 weeks apoptotic cells are
no longer detectable.
DISCUSSION
The choice of a rabbit femoral artery injury
model to study the effects of ASbFGF gene delivery
on the arterial response to injury was made for sev-
eral reasons. There can be significant variability
between species with respect to the efficacy of a par-
ticular intervention or agent on the intimal thicken-
ing response to vascular injury. Whereas Powell et
al.13 demonstrated an 80% reduction in intimal
hyperplasia induced by balloon catheterization of rat
carotid arteries by administration of the angiotensin-
converting enzyme inhibitor, Cilazapril, this could
not be reproduced by Hanson et al.14 in baboons. In
the Hanson study, baboons were administered suffi-
cient doses of Cilazapril to almost completely inhib-
it plasma ACE activity, but no significant reduction
in intimal thickening could be appreciated in a vari-
ety of vascular injury models. Although efficacy in
rabbits does not guarantee success in primates or
specifically in human beings, reproducibility in more
than one animal model increases the likelihood that
a particular approach might be suitable for clinical
application.
Concern has been raised about the inflammato-
ry reaction to the virus itself stimulating neointimal
hyperplasia, particularly in rabbit femoral arter-
ies,15 thereby potentially limiting the efficacy of
virally encoded therapeutic genes. Although we did
not specifically examine the inflammatory reaction
to viral delivery with regard to inflammatory mark-
ers, a significant inflammatory response could be
seen surrounding the vessels treated with aden-
ovirus 4 days after injury and vector delivery. The
demonstrated efficacy of Ad.ASbFGF in reducing
Fig. 2. Hematoxylin and eosin–stained photomicrographs of rabbit superficial femoral arteries
14 days after balloon injury. A, Treated with Ad.lacZ at 1 ´ 1010 pfu/ml. B, Treated with PBS
vehicle alone. C, Treated with Ad.ASbFGF at 1 ´ 1010 pfu/ml. All treatment solutions were
delivered as a local intraluminal incubation for 20 minutes, placed immediately after balloon
injury and brief PBS irrigation. These photomicrographs demonstrate a marked inhibition of
neointimal thickening in the Ad.ASbFGF-treated vessels. Original magnification, ´125.
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intimal thickening in this model suggests that sig-
nificant inflammatory reactivity to the virus is not
limiting in this context.
There are important differences in the biologic
properties and structure of different vessels that con-
tribute to altering the response to injury, so it is
important to study the mechanism of vascular injury
at different sites. Because femoral artery angioplasty
is currently a widespread clinical treatment method,
studies of femoral artery injury mechanisms and
potential interventions are indicated.
The major advantages of adenoviral gene deliv-
ery are that gene transfer and gene expression are
highly efficient and that cellular proliferation is not
required to produce transgene product.20 In addi-
tion to the advantages of using adenoviral vectors for
gene delivery, the disadvantages commonly reported
do not seem to be as problematic for application to
the vasculature as to other organ systems and tissues.
The disadvantages of transient expression as a result
of the immune response to viral antigens and the
lack of chronic integration may be a relative advan-
tage in the context of vascular injury because most
major events that lead to intimal thickening have
taken place by 2 weeks after injury.21 In addition,
the potential systemic toxicity of the virus can be
averted by local delivery. Lastly, the vascular barrier
that inhibits viral delivery to other target organs in
nonvascular studies is the vascular target. We have
shown that the vessel readily takes up virus and pro-
duces gene product after balloon injury and local
intraluminal dwelling of virus solution. Other inves-
tigators have also demonstrated, in a variety of mod-
els of vascular injury, significant inhibition of neoin-
timal thickening after transient gene delivery.22
Concern has been raised in the past as to the
specificity of antisense-based therapies, particularly
relating to the use of oligonucleotides.23 We have
addressed this by transfecting a full-length antisense
sequence, which should have a very high specificity
for its target. Consequently, unlike with oligonu-
cleotides, there is no similar “missense” control. The
most appropriate control remains a similar aden-
ovirus carrying a commonly used reporter gene. In
addition, we have previously shown in vitro that the
provocation of cell death by ASbFGF can be pre-
vented by exogenous bFGF and not by exogenous
epidermal growth factor, further suggesting that the
effects of ASbFGF are specific to bFGF production
and function.
The virally encoded ASbFGF RNA was designed
to inhibit de novo synthesis of bFGF to study the
contribution of ongoing bFGF production on the
arterial response to balloon injury. We have previ-
ously shown in the rat carotid artery injury model
that Ad.ASbFGF inhibits intimal thickening in a
dose-dependent fashion when administered by local
intraluminal incubation immediately after balloon
injury.11 The current study documents the effects of
Ad.ASbFGF in inhibiting intimal thickening in a sec-
ond animal model and supports the concept that
ongoing production of bFGF plays an important
role in the arterial response to injury. It is important
to note, however, that these effects are seen at the
relatively early time point of 2 weeks after injury.
Further studies are needed to determine whether
these effects are indeed durable over the long term.
In attempting to elucidate the mechanisms
involved in the limitation of intimal thickening asso-
ciated with the intraluminal delivery of Ad.ASbFGF,
proliferating cells were labeled by incorporation of
BrdU. In addition, sections were evaluated by
TUNEL reaction and fluorescence microscopy for
biochemical evidence of apoptosis. Studies of prolif-
eration and apoptosis were performed on tissue sec-
Fig. 3. I/M thickness ratios 14 days after balloon injury
immediately followed by a 20-minute local incubation of
treatment solution. Treatment groups included PBS vehi-
cle alone, Ad.lacZ at 1 ´ 1010 pfu/ml, and Ad.ASbFGF at
1 ´ 1010 pfu/ml. Graph demonstrates significant reduc-
tion in intimal thickening in Ad.ASbFGF group compared
with PBS and Ad.lacZ control groups (p = 0.004 and p <
0.0001, respectively). There was no significant difference
in intimal thickening between the PBS and Ad.lacZ
groups (p = 0.27).
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tions harvested from animals at both 4 days and 14
days after superficial femoral artery injury and treat-
ment. No significant difference was demonstrated in
the medial proliferation index of Ad.ASbFGF-treat-
ed and Ad.lacZ-treated vessels at 4 and 14 days after
injury and in the intimal proliferative index at 14
days after injury. However, an increase in apoptosis
was noted in the medial cells of Ad.ASbFGF-treated
vessels 4 days after injury. There was minimal evi-
dence of apoptosis in the vessels treated with
Ad.lacZ at the same time point. By 2 weeks after bal-
loon injury and gene delivery, there was no evidence
of apoptosis in vessels of either treatment group.
These data would suggest that the effect of
Ad.ASbFGF gene delivery on the limitation of inti-
mal thickening after balloon injury is not mediated
by a significant inhibition of cellular proliferation, as
seems to be the case when initial bFGF released by
injured and dying cells is blocked by antibody,3,6 but
rather by induction of apoptosis and cellular demise.
These findings are consistent with the in vitro data
previously reported by Fox and Shanley16 and sug-
gest that sustained bFGF signaling is critical to the
survival of vascular SMCs in vitro and in vivo. It
would appear that loss of SMCs by apoptosis in the
early phase leads to fewer cells actually proliferating
(at a rate not significantly altered); therefore, there
would be fewer cells depositing extracellular matrix,
thereby limiting intimal thickening by 14 days after
injury. Further studies to evaluate this theory are
warranted.
CONCLUSION
Our data suggest that the use of Ad.ASbFGF
gene transfer, designed to inhibit de novo bFGF
synthesis after balloon injury, results in a significant
Fig. 4. Indirect fluorescence microscopy of rabbit superficial femoral artery segments 4 days
after balloon injury, treated with either Ad.lacZ at 1 ´ 1010 pfu/ml or Ad.ASbFGF at 1 ´ 1010
pfu/ml by local intraluminal incubation immediately after injury. A, C, and E, Red emission
demonstrates propidium iodide counterstained nuclei (visualizing all nuclei present) of
Ad.lacZ-treated, negative control, and Ad.ASbFGF-treated vessels, respectively. B, D, and F,
Green emission visualizes FITC-labeled nuclei of cells undergoing apoptosis of Ad.lacZ-treat-
ed, negative control, and Ad.ASbFGF-treated vessels, respectively. Images demonstrate an
increase in apoptotic cells in media of Ad.ASbFGF-treated vessel (F) compared with Ad.lacZ-
treated vessels or negative control. Negative controls were of an Ad.ASbFGF-treated vessel
stained in parallel with other sections but incubated in the absence of terminal deoxynu-
cleotidyl transferase (TdT) enzyme. Original magnification, ´125.
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inhibition of neointimal formation. Continued
bFGF synthesis may contribute to the arterial
response to injury in rabbits by sustaining SMC sur-
vival in the neointima. Ad.ASbFGF gene transfer
may be an effective strategy in limiting the intimal
hyperplastic response after vascular reconstructive
procedures.
We appreciate the technical assistance of Jason Shanley
and Puthiyaveettil N. Raghunath, PhD.
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